Effect of manual lymph drainage in addition to guidelines and exercise therapy on arm lymphoedema related to breast cancer: randomised controlled trial. 2011

Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
Department of Rehabilitation Sciences, Katholieke Universiteit Leuven and Department of Physiotherapy, University Hospitals Leuven, Leuven, Belgium. nele.devoogdt@uzleuven.be

OBJECTIVE To determine the preventive effect of manual lymph drainage on the development of lymphoedema related to breast cancer. METHODS Randomised single blinded controlled trial. METHODS University Hospitals Leuven, Leuven, Belgium. METHODS 160 consecutive patients with breast cancer and unilateral axillary lymph node dissection. The randomisation was stratified for body mass index (BMI) and axillary irradiation and treatment allocation was concealed. Randomisation was done independently from recruitment and treatment. Baseline characteristics were comparable between the groups. METHODS For six months the intervention group (n = 79) performed a treatment programme consisting of guidelines about the prevention of lymphoedema, exercise therapy, and manual lymph drainage. The control group (n = 81) performed the same programme without manual lymph drainage. METHODS Cumulative incidence of arm lymphoedema and time to develop arm lymphoedema, defined as an increase in arm volume of 200 mL or more in the value before surgery. RESULTS Four patients in the intervention group and two in the control group were lost to follow-up. At 12 months after surgery, the cumulative incidence rate for arm lymphoedema was comparable between the intervention group (24%) and control group (19%) (odds ratio 1.3, 95% confidence interval 0.6 to 2.9; P = 0.45). The time to develop arm lymphoedema was comparable between the two group during the first year after surgery (hazard ratio 1.3, 0.6 to 2.5; P = 0.49). The sample size calculation was based on a presumed odds ratio of 0.3, which is not included in the 95% confidence interval. This odds ratio was calculated as (presumed cumulative incidence of lymphoedema in intervention group/presumed cumulative incidence of no lymphoedema in intervention group)×(presumed cumulative incidence of no lymphoedema in control group/presumed cumulative incidence of lymphoedema in control group) or (10/90)×(70/30). CONCLUSIONS Manual lymph drainage in addition to guidelines and exercise therapy after axillary lymph node dissection for breast cancer is unlikely to have a medium to large effect in reducing the incidence of arm lymphoedema in the short term. Trial registration Netherlands Trial Register No NTR 1055.

UI MeSH Term Description Entries
D008196 Lymph The interstitial fluid that is in the LYMPHATIC SYSTEM. Lymphs
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008209 Lymphedema Edema due to obstruction of lymph vessels or disorders of the lymph nodes. Milroy's Disease,Congenital Familial Lymphedema,Congenital Hereditary Lymphedema,Early Onset Lymphedema,Hereditary Lymphedema,Hereditary Lymphedema 1,Hereditary Lymphedema Type I,Lymphedema, Early-Onset,Lymphedema, Hereditary, Ia,Milroy Disease,Nonne-Milroy Disease,Nonne-Milroy Lymphedema,Nonne-Milroy-Meige Disease,Primary Congenital Lymphedema,Congenital Hereditary Lymphedemas,Congenital Lymphedema, Primary,Congenital Lymphedemas, Primary,Early Onset Lymphedemas,Early-Onset Lymphedema,Early-Onset Lymphedemas,Hereditary Lymphedema 1s,Hereditary Lymphedema, Congenital,Hereditary Lymphedemas,Hereditary Lymphedemas, Congenital,Lymphedema, Congenital Hereditary,Lymphedema, Early Onset,Lymphedema, Hereditary,Lymphedema, Nonne-Milroy,Lymphedema, Primary Congenital,Lymphedemas,Lymphedemas, Congenital Hereditary,Lymphedemas, Early Onset,Lymphedemas, Early-Onset,Lymphedemas, Hereditary,Lymphedemas, Primary Congenital,Milroys Disease,Nonne Milroy Disease,Nonne Milroy Lymphedema,Nonne Milroy Meige Disease,Primary Congenital Lymphedemas
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004322 Drainage The removal of fluids or discharges from the body, such as from a wound, sore, or cavity.
D005081 Exercise Therapy A regimen or plan of physical activities designed and prescribed for specific therapeutic goals. Its purpose is to restore normal musculoskeletal function or to reduce pain caused by diseases or injuries. Rehabilitation Exercise,Remedial Exercise,Therapy, Exercise,Exercise Therapies,Exercise, Rehabilitation,Exercise, Remedial,Exercises, Rehabilitation,Exercises, Remedial,Rehabilitation Exercises,Remedial Exercises,Therapies, Exercise
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
July 2004, Breast cancer research and treatment,
Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
January 2005, Lymphatic research and biology,
Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
March 2011, BMC cancer,
Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
February 2018, European journal of obstetrics, gynecology, and reproductive biology,
Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
September 2017, European journal of cancer care,
Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
November 2020, Breast cancer research and treatment,
Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
February 2023, Cancers,
Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
November 2018, British journal of cancer,
Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
December 2002, European journal of cancer care,
Nele Devoogdt, and Marie-Rose Christiaens, and Inge Geraerts, and Steven Truijen, and Ann Smeets, and Karin Leunen, and Patrick Neven, and Marijke Van Kampen
July 2014, BMC complementary and alternative medicine,
Copied contents to your clipboard!